title: Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.
authors.affiliation: National Cancer Institute, IL-2/LAK Extramural Working Group, Bethesda, Maryland 20892.
authors.forename: M
authors.initials: M
authors.lastname: Sznol
authors.forename: J P
authors.initials: JP
authors.lastname: Dutcher
authors.forename: M B
authors.initials: MB
authors.lastname: Atkins
authors.forename: A R
authors.initials: AR
authors.lastname: Rayner
authors.forename: K A
authors.initials: KA
authors.lastname: Margolin
authors.forename: E R
authors.initials: ER
authors.lastname: Gaynor
authors.forename: G R
authors.initials: GR
authors.lastname: Weiss
authors.forename: F
authors.initials: F
authors.lastname: Aronson
authors.forename: D R
authors.initials: DR
authors.lastname: Parkinson
authors.forename: M J
authors.initials: MJ
authors.lastname: Hawkins
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology*; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2